Chimeric MSP-based malaria vaccine

Details Chimeric MSP-based malaria vaccine Chimeric MSP-based malaria vaccine

2011-04-26

2011-04-26

Graser, Jennifer E (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Parasitic organism or component thereof or substance...

C424S269100, C424S191100, C424S193100, C424S194100, C424S192100

Reexamination Certificate

active

07931908

ABSTRACT:
The invention provides an immunogenic composition comprising MSPk-8 linked to an antigen. Methods of using the composition to induce an immune response in an animal are also provided.

REFERENCES:
patent: 4837016 (1989-06-01), Holder et al.
patent: 5597708 (1997-01-01), Holder et al.
patent: 5720959 (1998-02-01), Holder et al.
patent: 6551586 (2003-04-01), Davidson et al.
patent: 6828416 (2004-12-01), Lal et al.
patent: 7101556 (2006-09-01), Pan
patent: 0 062 924 (1982-10-01), None
patent: 2 096 893 (1982-10-01), None
patent: 2 099 300 (1982-12-01), None
Mikayama et al. (Nov. 1993. Proc.Natl.Acad.Sci. USA, vol. 90 : 10056-10060).
Rudinger et al. (Jun. 1976. Peptide Hormones. Biol.Council. pp. 5-7).
Greenspan et al (Nature Biotechnology 1999. vol. 7. pp. 936-937).
Chothia et al (The EMBO Journal, 1986, 5/4:823-26).
Black et al., “Merozoite surface protein 8 ofPlasmodium falciparumcontains two epidermal growth factor-like domains”, Molecular and Biochemical Parasitology, 2001, 114(2): 217-226.
Blackman et al., “A Single Fragment of a Malaria Merozoite Surface Protein Remains on the Parasite During Red Cell Invasion and Is the Target of Invasion-inhibiting Antibodies”, J. Exp. Med., 1990, 172: 379-382.
Blackman et al., “Proteolytic processing of thePlasmodium falciparummerozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains”, Mol. Biochem. Parasitol., 1991, 49(1): 29-33, Abstract only.
Burghaus et al., “Immunization ofAotus nancymaiwith Recombinant C Terminus ofPlasmodium falciparumMerozoite Surface Protein 1 in Liposomes and Alum Adjuvant Does Not Induce Protection against a Challenge Infection”, Infection and Immunity, 1996, 64(9): 3614-3619.
Burns et al., “Protection againstPlasmodium chabaudimalaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4”, Infection and Immunity, 2004, 72(10):5605-12.
Burns et al., “A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite,Plasmodium yoelii”, J. Immunol., 1989, 143: 2670-2676.
Burns et al., “Protection againstPlasmodium yoellimalaria induced by immunization with particulate blood-stage antigens”, Infection and Immunity, 1997, 65(8):3138-3145.
Chang et al., “A Recombinant Baculovirus 42-Kilodalton C-Terminal Fragment ofPlasmodium falciparumMerozoite Surface Protein 1 Protects Aotus Monkeys against Malaria”, Infection and Immunity, 1996, 64(1): 253-261.
Cheung et al., “Cloning and expression inEscherichia coliof a surface antigen ofPlasmodium falciparummerozoites”, The EMBO Journal, 1985, 4(4): 1007-1012.
Daly et al., “Influence of Adjuvants on Protection Induced by a Recombinant Fusion Protein against Malarial Infection”, Infection and Immunity, 1996, 64(7): 2602-2608.
Darko et al., “The Clinical-Grade 42-Kilodalton Fragment of Merozoite Surface Protein 1 ofPlasmodium falciparumStrain FVO Expressed inEscherichia coliProtectsAotus nancymaiagainst Challenge with Homologous Erythrocytic-Stage Parasites”, Infection and Immunity, 2005, 73(1): 287-297.
Drew et al., “A Common Cross-species Function for the Double Epidermal Growth Factor-like Modules of the Highly Divergent Plasmodium Surface Proteins MSP-1 and MSP-8”, The Journal of Biological Chemistry, 2004, 279(19): 20147-20158.
Drew et al., “Plasmodium falciparumMerozoite Surface Protein 8 Is a Ring-Stage. Membrane Protein That Localizes to the Parasitophorous Vacuole of Infected Erythrocytes”, Infection and Immunity, 2005, 73(7): 3912-3922.
Egan et al., “Serum Antibodies from Malaria-Exposed People Recognize Conserved Epitopes Formed by the Two Epidermal Growth Factor Motifs of MSP119, the Carboxy-Terminal Fragment of the Major Merozoite Surface Protein ofPlasmodium falciparum”, Infection and Immunity, 1995, 63(2): 456-466.
Freeman et al., “Surface Antigens of Malaria Merozoites”, J. Exp. Med., 1983, 158: 1647-1653.
Gilson et al., “Identification and stoichiometry of GPI-anchored membrane proteins of the human malaria parasitePlasmodium falciparum”, MCP Papers in Press. Published on Apr. 7, 2006 as Manuscript M600035-MCP200.
Malaria Vaccine Initiative,FalciparumMalaria MSP1 Workshop Progress Toward MSP1 Vaccine Development and Testing, Dec. 4, 2000 [online], [retrieved on Feb. 6, 2008]. Retrieved from the Internet <URL:www.malariavaccine.org/files/msp1-wksp.pdf.
Holder et al., “Primary structure of the precursor to the three major surface antigens ofPlasmodium falciparummerozoites”, Nature, 1985, 317(6034): 270-273, Abstract only.
Holder et al., “The Three Major Antigens on the Surface ofPlasmodium falciparumMerozoites are Derived from a Single High Molecular Weight Precursos”, J Exp Med. 1984, 160:624-629.
Kumar et al., “Immunogenicity and in Vivo Efficiency of RecombinantPlasmodium falciparumMerozoite Surface Protein-1 inAotusMonkeys”, Mol Med., 1995, 1:325-332.
Kumar et al., “Immunogenicity and Efficacy inAotusMonkeys of Four RecombinantPlasmodium falciparumVaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1”, Infection and Immunity, 2000, 68(4): 2215-2223.
Lyon et al., “Epitope map and processing scheme for the 195,000-dalton surface glycoprotein ofPlasmodium falciparummerozoites deduced from cloned overlapping segments of the gene”, Proc. Natl. Acad. Sci. USA, 1986, 83: 2989-2993.
Mackay et al., “Polymorphism of the precursor for the major surface antigens ofPlasmodium falciparummerozoites: studies at the genetic level”, The EMBO Journal, 1985, 4(13B): 3823-3829.
Mahanty et al., “Progress in the development of recombinant and synthetic blood-stage malaria vaccines”, The Journal of Experimental Biology, 2003, 206: 3781-3788.
Mello et al., “Members of the merozoite surface protein 7 family with similar expression patterns differ in ability to protect againstPlasmodium yoeliimalaria”, Infection and Immunity, 2004, 72(2):1010-8.
O'Donnell et al., “Antibodies Against Merozoite Surface Protein (MSP)-119 are a Major Component of the Invasion-inhibitory Response in Individuals Immune to Malaria”, J. Exp. Med., 2001, 193(12): 1403-1412.
O'Donnell et al., “Functional conservation of the malaria vaccine antigen MSP-119 across distantly relatedPlasmodiumspecies”, Nature Medicine, 2000, 6(1): 91-95.
Shi et al., “Alteration in Host Cell Tropism Limits the Efficacy of Immunization with a Surface Protein of Malaria Merozoites”, Infection and Immunity, 2005, 73(10): 6363-6371.
Shi et al., “Improved immunogenicity and protective efficacy of a chimeric MSP-1 and MSP-8 recombinant antigen vaccine”, Poster abstract, ASTMH 55th Annual Meeting, Nov. 12-16, 2006.
Shi et al., “Enhanced Protection against Malaria by a Chimeric Merozoite Surface Protein Vaccine”, Infection and Immunity, 2007, 75(3): 1349-1358.
Shi et al., “Expression, localization, and erythrocyte binding activity ofPlasmodium yoeliimerozoite surface protein-8”, Mol Biochem Parasitol., 2006, 149(2):231-41. Epub 2006 Jun. 30.
Stowers et al., “Efficacy of Two Alternate Vaccines Based onPlasmodium falciparumMerozoite Surface Protein 1 in anAotusChallenge Trial”, Infection and Immunity, 2001, 69(3): 1536-1546.
Tanabe et al., “Allelic dimorphism in a surface antigen gene of the malaria parasitePlasmodium falciparum”, J. Mol. Biol., 1987, 195(2): 273-287, Abstract only.
Holder, 1996, pp. 77-104. In: S. L. Hoffman (ed), Malaria vaccine development: a multi-immune response approach, ASM Press, Washington DC.
Galinski et al., 2005, pp. 113-168, “A Mechanistic Appro

Affiliated with

Also associated with

Rating

Chimeric MSP-based malaria vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric MSP-based malaria vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric MSP-based malaria vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2641603